* Genome Therapeutics Corp., of Waltham, Mass., delivered a customized bioinformatics platform to Schering-Plough Corp., of Madison, N.J., as part of their collaboration to discover anti-infective agents to be used against drug-resistant bacteria, including Staphylococcus aureus. The delivery triggers a milestone payment to Genome Therapeutics, but terms were not disclosed. Since the $43.5 million partnership began in December 1995, this is the fifth milestone reached.
* Medarex Inc., of Annandale, N.J., gained a European patent on the HuMAb-Mouse technology, triggering a $7.5 million payment to Medarex from Xenotech LP, a joint-venture alliance of Cell Genesys Inc., of Foster City, Calif.; Abgenix Inc., of Fremont, Calif., a subsidiary of Cell Genesys; and Japan Tobacco Inc., of Tokyo. The patent covers technology for making fully human antibodies from transgenic mice. The payment is a portion of the Xenotech group's obligation under a cross-license agreement, which calls for additional payments of up to $22.5 million.
* NaviCyte Inc., of Sparks, Nev., executed a license agreement with the Memorial Sloan-Kettering Institute for Cancer Research, in New York, for an undisclosed amount. The license grants NaviCyte exclusive worldwide rights and sublicense rights to commercial applications of the Caco-2 cell line and its derivatives. Developed by Sloan-Kettering researchers, Caco-2 is an immortalized human colonic carcinoma cell line.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo., began a Phase II trial for MiKasome, its proprietary liposomal formulation of the antibiotic amikacin. The drug will be tested against complicated urinary tract infections in 30 patients at three sites. A variety of outcomes will be monitored, including overall safety, improvement of symptoms, elimination of bacterial infection and prevention of recurrence four to six weeks after treatment.